



Author Correction: Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Correction to: *Nature Medicine*

<https://doi.org/10.1038/s41591-024-02986-9>, published online 3 June 2024.

<https://doi.org/10.1038/s41591-024-03175-4>

Published online: 9 July 2024

Franck Morschhauser , Saurabh Dahiya, M. Lia Palomba , Alejandro Martin Garcia-Sancho, Juan Luis Reguera Ortega, John Kuruvilla, Ulrich Jäger , Guillaume Cartron, Koji Izutsu , Martin Dreyling, Brad Kahl, Hervé Ghesquieres, Kirit Ardeshra, Hideki Goto, Anna Maria Barbui, Jeremy S. Abramson , Peter Borchmann, Isabelle Fleury, Stephan Mielke, Alan Skarbnik, Sven de Vos, Manali Kamdar, Reem Karmali , Andreas Viardot, Thalia Farazi, Omotayo Fasan, James Lymp, Min Vederal, Rina Nishii, Ariel Avilion, Jessica Papuga, Jinender Kumar & Loretta J. Nastoupil

In the version of the article initially published, in the Japan row of Supplementary Fig. 2, the values for the columns “Evaluable patients” and “Patients with ORR” were originally both 8 but have now been amended to 9. A corrected Supplementary Information file has now been uploaded online.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024